Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
Subscribe To Our Newsletter & Stay Updated
